MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP

References

• Zucca E, Rohatiner A, Magrath I, Cavalli F. Epidemiology and management of lymphoma in low-income countries. Hematol Oncol. 2011;29(1):1–4. doi:10.1002/hon.945
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T, Bunworasate U, Wudhikarn K, et al. Non-Hodgkin lymphoma in South East Asia: an analysis of the histopathology, clinical features, and survival from Thailand. Hematol Oncol. 2018;36(1):28–36. doi:10.1002/hon.2392
   PubMed Web of Science ®Google Scholar
• Fisher SG, Fisher RI. The epidemiology of non-Hodgkin’s lymphoma. Oncogene. 2004;23(38):6524–6534. doi:10.1038/sj.onc.1207843
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190. doi:10.1200/JCO.2010.28.1618
   PubMed Web of Science ®Google Scholar
• Perry AM, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016;101(10):1244–1250. doi:10.3324/haematol.2016.148809
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842. doi:10.1182/blood-2013-09-524108
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. doi:10.1038/35000501
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947. doi:10.1056/NEJMoa012914
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–2323. doi:10.1056/NEJMoa0802885
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–207. doi:10.1200/JCO.2010.30.0368
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Schmidt-Hansen M, Berendse S, Marafioti T, McNamara C. Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review. Leuk Lymphoma. 2017;58(10):2403–2418. doi:10.1080/10428194.2017.1287364
   PubMed Web of Science ®Google Scholar
• Oh S, Koo DH, Suh C, et al. Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy. J Korean Med Sci. 2011;26(12):1556–1562. doi:10.3346/jkms.2011.26.12.1556
   PubMed Web of Science ®Google Scholar
• Mishra D, Singh S, Narayan G. Role of B cell development marker CD10 in cancer progression and prognosis. Mol Biol Int. 2016;2016:4328697. doi:10.1155/2016/4328697
   PubMedGoogle Scholar
• Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol. 2001;115(4):582–588. doi:10.1309/84GE-U85A-FMU0-7AUV
   PubMed Web of Science ®Google Scholar
• LeBien TW, McCormack RT. The common acute lymphoblastic leukemia antigen (CD10)–emancipation from a functional enigma. Blood. 1989;73(3):625–635. doi:10.1182/blood.V73.3.625.625
   PubMed Web of Science ®Google Scholar
• Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD, Melnick AM. The expanding role of the BCL6 oncoprotein as a cancer therapeutic target. Clin Cancer Res. 2017;23(4):885–893. doi:10.1158/1078-0432.CCR-16-2071
   PubMed Web of Science ®Google Scholar
• Sofo-Hafizovic A, Chikha A, Gojak R, Hadzimesic ES. Expression IRF/MUM1>25% predictor to three-year survival of diffuse large B cell lymphoma in the immunochemotherapy era. Med Arch. 2016;70(5):342–347. doi:10.5455/medarh.2016.70.342-347
   PubMedGoogle Scholar
• Carbone A, Gloghini A, Cozzi MR, et al. Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis. Br J Haematol. 2000;111(1):247–257. doi:10.1046/j.1365-2141.2000.02329.x
   PubMed Web of Science ®Google Scholar
• Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566–1572. doi:10.3892/mmr.2014.2914
   PubMed Web of Science ®Google Scholar
• Iatropoulos MJ, Williams GM. Proliferation markers. Exp Toxicol Pathol. 1996;48(2–3):175–181. doi:10.1016/S0940-2993(96)80039-X
   PubMedGoogle Scholar
• Babu G, Lakshmaiah K, Dasappa L, et al. Ki-67 and subtype as prognostic and predictive markers of diffuse large B-cell lymphoma. Clin Cancer Investigat J. 2017;6(1):97–102. doi:10.4103/ccij.ccij_12_17
   Web of Science ®Google Scholar
• Li ZM, Huang JJ, Xia Y, et al. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Eur J Haematol. 2012;88(6):510–517. doi:10.1111/j.1600-0609.2012.01778.x
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Ridell B, Sigurdardottir M, Hansson U, Nilsson-Ehle H, Andersson PO. Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(8):1501–1509. doi:10.1080/10428190802140055
   PubMed Web of Science ®Google Scholar
• He X, Chen Z, Fu T, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;14:153. doi:10.1186/1471-2407-14-153
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications–a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805–812. doi:10.1200/JCO.2006.09.4490
   PubMed Web of Science ®Google Scholar
• Gogia A, Das CK, Kumar L, et al. Diffuse large B-cell lymphoma: an institutional analysis. South Asian J Cancer. 2018;7(3):200–202. doi:10.4103/sajc.sajc_65_18
   PubMed Web of Science ®Google Scholar
• Dwivedi A, Mehta A, Solanki P. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival. Indian J Pathol Microbiol. 2015;58(4):453–458. doi:10.4103/0377-4929.168886
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Sinclair N, Beltran BE, et al. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013;37(4):386–391. doi:10.1016/j.leukres.2013.01.002
   PubMed Web of Science ®Google Scholar
• Zhao H, Kan Y, Wang X, Chen L, Ge P, Qian Z. Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma. Biosci Rep. 2019;39:8. doi:10.1042/BSR20191162
   Web of Science ®Google Scholar
• Ng CJ, Teo CH, Abdullah N, Tan WP, Tan HM. Relationships between cancer pattern, country income and geographical region in Asia. BMC Cancer. 2015;15:613. doi:10.1186/s12885-015-1615-0
   PubMed Web of Science ®Google Scholar
• Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol. 2005;18(8):1113–1120. doi:10.1038/modpathol.3800396
   PubMed Web of Science ®Google Scholar
• Lu TX, Miao Y, Wu JZ, et al. The distinct clinical features and prognosis of the CD10(+)MUM1(+) and CD10(-)Bcl6(-)MUM1(-) diffuse large B-cell lymphoma. Sci Rep. 2016;6:20465. doi:10.1038/srep20465
   PubMed Web of Science ®Google Scholar
• Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28(4):464–470. doi:10.1097/00000478-200404000-00005
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78–84. doi:10.1182/blood-2002-04-1286
   PubMed Web of Science ®Google Scholar
• Xu Y, McKenna RW, Molberg KH, Kroft SH. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol. 2001;116(2):183–190. doi:10.1309/J7RN-UXAY-55GX-BUNK
   PubMed Web of Science ®Google Scholar
• Fabiani B, Delmer A, Lepage E, et al. CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch. 2004;445(6):545–551. doi:10.1007/s00428-004-1129-7
   PubMed Web of Science ®Google Scholar
• Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107(11):4207–4213. doi:10.1182/blood-2005-10-4222
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Dictor M, et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma–a Nordic Lymphoma Group study. Ann Hematol. 2004;83(7):414–419. doi:10.1007/s00277-004-0855-x
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29(3):389–396. doi:10.1002/stem.592
   PubMed Web of Science ®Google Scholar
• Li S, Wang Z, Lin L, et al. BCL6 rearrangement indicates poor prognosis in diffuse large B-cell lymphoma patients: a meta-analysis of cohort studies. J Cancer. 2019;10(2):530–538. doi:10.7150/jca.25732
   PubMed Web of Science ®Google Scholar
• De Mello CA, De Andrade VP, De Lima VC, Carvalho AL, Soares FA. Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. Leuk Lymphoma. 2011;52(8):1495–1503. doi:10.3109/10428194.2011.573032
   PubMed Web of Science ®Google Scholar
• Ichiki A, Carreras J, Miyaoka M, et al. Clinicopathological analysis of 320 cases of diffuse large B-cell lymphoma using the Hans classifier. J Clin Exp Hematop. 2017;57(2):54–63. doi:10.3960/jslrt.17029
   PubMedGoogle Scholar